Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM - Get Free Report) in a report released on Thursday. The firm set a "hold" rating on the biopharmaceutical company's stock.

ALIM has been the topic of a number of other reports. Alliance Global Partners reissued a "neutral" rating on shares of Alimera Sciences in a report on Tuesday, June 25th. HC Wainwright cut shares of Alimera Sciences from a "buy" rating to a "neutral" rating and set a $6.00 target price on the stock. in a report on Tuesday, June 25th. Finally, Maxim Group reissued a "hold" rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Stock Down 0.2 %

Shares of ALIM stock traded down $0.01 on Thursday, hitting $5.54. The stock had a trading volume of 2,257,947 shares, compared to its average volume of 220,272. The firm has a market capitalization of $290.24 million, a price-to-earnings ratio of -3.54 and a beta of 1.28. The stock's 50 day moving average is $5.47 and its 200-day moving average is $4.19. The company has a debt-to-equity ratio of 1.71, a quick ratio of 2.51 and a current ratio of 2.62. Alimera Sciences has a 52-week low of $2.61 and a 52-week high of $5.65.

Alimera Sciences (NASDAQ:ALIM - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. As a group, research analysts expect that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Trading of Alimera Sciences

A number of large investors have recently modified their holdings of ALIM. Fifth Lane Capital LP acquired a new stake in shares of Alimera Sciences in the 1st quarter worth about $83,000. Vanguard Group Inc. increased its holdings in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company's stock worth $4,077,000 after acquiring an additional 396,506 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in shares of Alimera Sciences in the 1st quarter worth about $169,000. Ancora Advisors LLC acquired a new stake in shares of Alimera Sciences in the 1st quarter worth about $915,000. Finally, Deltec Asset Management LLC acquired a new stake in shares of Alimera Sciences in the 2nd quarter worth about $690,000. Institutional investors and hedge funds own 99.83% of the company's stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).